TY  - GEN
AU  - Joensuu,Heikki
AU  - Wardelmann,Eva
AU  - Sihto,Harri
AU  - Eriksson,Mikael
AU  - Sundby Hall,Kirsten
AU  - Reichardt,Annette
AU  - Hartmann,Jörg T
AU  - Pink,Daniel
AU  - Cameron,Silke
AU  - Hohenberger,Peter
AU  - Al-Batran,Salah-Eddin
AU  - Schlemmer,Marcus
AU  - Bauer,Sebastian
AU  - Nilsson,Bengt
AU  - Kallio,Raija
AU  - Junnila,Jouni
AU  - Vehtari,Aki
AU  - Reichardt,Peter
TI  - Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial
SN  - 2374-2445
PY  - 2017///0731
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Chemotherapy, Adjuvant
KW  - DNA Mutational Analysis
KW  - methods
KW  - DNA, Neoplasm
KW  - genetics
KW  - Drug Administration Schedule
KW  - Female
KW  - Gastrointestinal Stromal Tumors
KW  - drug therapy
KW  - Humans
KW  - Imatinib Mesylate
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Proto-Oncogene Mas
KW  - Proto-Oncogene Proteins c-kit
KW  - Receptor, Platelet-Derived Growth Factor alpha
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1001/jamaoncol.2016.5751
ER  -